When Screen Time Becomes Medicine: The Rise of FDA-Approved Digital Therapeutics for Children

For decades, the standard medical advice regarding children and screens has been a simple directive: limit them. Pediatricians have long warned that excessive screen time can disrupt sleep, displace physical activity, and fragment attention spans. But a quiet revolution in regulatory science is flipping that paradigm on its head. A new class of medical interventions, known as prescription digital therapeutics, is proving that when software is engineered with clinical precision, screen time can actually become medicine.[4]

The shift is being driven by the U.S. Food and Drug Administration's increasing willingness to authorize "Software as a Medical Device" (SaMD). Unlike the thousands of unregulated wellness apps available on consumer app stores, these digital therapeutics must undergo rigorous, multi-year clinical trials to prove their safety and efficacy. They are prescribed by doctors, dispensed with dosage limits, and designed to target specific neurological pathways.[4]

The flagship example of this new era is EndeavorRx, developed by Akili Interactive. In 2020, it made history by becoming the first video game to receive FDA clearance as a medical treatment for any condition, specifically targeting children ages 8 to 12 with attention-deficit/hyperactivity disorder (ADHD). On the surface, the software looks like a standard mobile action game where players steer a hovercraft down a winding track while collecting targets and dodging obstacles.[1][3]

Beneath the colorful graphics, however, runs a proprietary algorithm known as the Selective Stimulus Management Engine. The game forces the child to multitask, requiring rapid, coordinated hand-eye movements that stimulate the specific neural networks in the prefrontal cortex responsible for cognitive control. Crucially, the software adapts in real-time, constantly adjusting the difficulty so the patient is always playing at the exact cusp of their cognitive ability, ensuring maximum neural training without causing overwhelming frustration.[3]

The clinical evidence supporting this approach is substantial. The FDA based its clearance on data from five clinical studies involving more than 600 children. In the largest randomized trial, published in The Lancet Digital Health, children played the game for 25 minutes a day, five days a week, for four weeks. Researchers measured the results using the Test of Variables of Attention (T.O.V.A.), an objective, computerized assessment of cognitive traits.[1]

The results demonstrated that 47 percent of children who played EndeavorRx showed significant improvement in their objective attention scores, compared to 32 percent in a control group playing a standard educational puzzle game. While the game is not intended to entirely replace traditional stimulant medications or behavioral therapy, it offers a potent adjunct or alternative, particularly for families hesitant about pharmaceutical side effects.[3]

Digital therapeutics are also remarkably safe compared to traditional pharmacology. The most common side effects reported in the clinical trials were mild frustration, occasional headaches, and dizziness. There were no serious adverse events, and unlike stimulant medications, the software does not suppress appetite, disrupt sleep architecture, or carry a risk of dependency. To prevent overuse, the game literally locks the child out after their prescribed 25-minute daily dose is complete.[1][3]

Beyond treatment, digital tools are now tackling one of the most severe bottlenecks in pediatric care: diagnosis. According to the CDC, approximately 1 in 36 children in the United States is identified with autism spectrum disorder. Yet, the pathway from a parent's first concern to a confirmed diagnosis often requires an evaluation by a developmental pediatrician or specialist—a workforce that has not scaled with demand. Families frequently face waitlists stretching from several months to over a year.

To bridge this gap, the FDA recently granted De Novo authorization to Canvas Dx, an AI-powered autism diagnostic aid developed by Cognoa. Designed for children ages 18 months to five years, the system allows parents to upload short videos of their child engaged in everyday activities like mealtime and play. An AI algorithm analyzes these behavioral inputs alongside a standardized parental questionnaire and a brief clinical assessment from a primary care provider.

By synthesizing these data points, the software can produce a positive or negative diagnostic result in a matter of weeks, moving the initial identification of autism out of backlogged specialty clinics and into standard primary care offices. This rapid turnaround is critical, as early intervention during the brain's most plastic developmental windows is known to significantly improve long-term outcomes for children on the spectrum.[4]

The success of these early pioneers has sparked a wave of innovation across pediatric medicine. Digital therapeutics are currently being developed and tested for a wide array of childhood conditions. For example, the FDA recently cleared a digital treatment for amblyopia (lazy eye) that uses modified virtual reality content to train the brain to use both eyes together, replacing the traditional, often stigmatizing, eye patch.

However, as the field of medical AI accelerates, researchers are raising important cautionary flags. A recent comprehensive study published in JAMA Pediatrics reviewed 876 FDA-authorized medical devices incorporating artificial intelligence and machine learning. The researchers found a glaring disparity: only 17 percent of these devices were explicitly labeled for use in children.[2]

More concerningly, among the AI devices authorized for pediatric use, only about one in five explicitly reported that they were developed and validated using pediatric datasets. The vast majority were trained exclusively on adult data or failed to report their training demographics entirely. Because children are not simply miniature adults—their anatomy, disease progression, and cognitive development are fundamentally different—algorithms trained on adult populations can produce biased or inaccurate outputs when applied to pediatric patients.[2]

This data gap has prompted pediatricians and researchers to advocate for stricter regulatory standards. They argue that the FDA must require manufacturers to explicitly disclose whether their algorithms were tested on children and to mandate pediatric-specific clinical validation before a device can be marketed for younger patients. Without these safeguards, the medical community risks exposing children to off-label AI use with unknown safety profiles.[2][4]

Despite these regulatory growing pains, the trajectory of digital therapeutics remains overwhelmingly positive. As insurance providers increasingly establish reimbursement codes for software prescriptions, these tools will become more accessible to families across the socioeconomic spectrum. By transforming the screens that children already gravitate toward into rigorously tested medical devices, the healthcare industry is unlocking a highly scalable, engaging, and effective new frontier in pediatric medicine.[4]